NASDAQ:ALNA - Allena Pharmaceuticals, Inc.
$6.35
 $-0.25
-3.79%
4:00PM EDT
2019-04-18
Allena Pharmaceuticals, Inc., incorporated on June 24, 2011 is a biopharmaceutical company. The Company is focused on developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Companys products candidate pipeline include ALLN-177, and ALLN-346. The Company is also focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, which can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The Companys proprietary technological enables to design and develop stable, non-absorbable oral enzyme therapies that remain in the gastrointestinal, or GI, tract, where the enzyme can degrade these metabolites, allowing for removal from the body through the bowel. The Companys lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ALNA     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 57   203. 85   241. 91  
42 stocks rank:  3. 75 K 1. 44 K 1. 05 K
# analyst opinions:  7. 00   14. 51   13. 97  
mean recommendation:  1. 50   2. 09   2. 01  

quick ratio:  10. 70   5. 27   1. 81  
current ratio:  11. 19   5. 62   2. 25  

target price low:  6. 37   84. 80   115. 21  
target price avg:  9. 69   111. 51   137. 51  
target price high:  6. 10   135. 81   157. 84  
1-yr high:  16. 50   114. 23   138. 78  
last close:  6. 35   87. 66   116. 69  
50-day avg:  6. 80   95. 54   123. 44  
200-day avg:  8. 78   94. 25   121. 11  
1-yr low:  5. 11   72. 78   98. 34  
volume:  8. 47 K 4. 11 M 8. 07 M
50-day avg volume:  41. 88 K 2. 76 M 5. 02 M
200-day avg volume:  44. 59 K 2. 92 M 4. 59 M

1-day return:  -3. 79 % -0. 41 % 0. 07 %
this week return:  3. 42 % -5. 74 % -4. 11 %
12-wk return:  -20. 82 % 1. 61 % -0. 05 %
52-wk return:  -51. 75 % 3. 12 % 8. 78 %

enterprise value (EV):  85. 72 M 48. 94 B 114. 64 B
market cap:  132. 18 M 43. 07 B 104. 73 B
EBITDA:  -35. 52 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -2. 41   4. 22   12. 73  
total debt:  9. 98 M 12. 24 B 16. 73 B
debt/equity:  20. 18   46. 71   89. 62  
net income (common):  -35. 65 M 2. 20 B 4. 20 B

shares outstanding:  20. 82 M 571. 70 M 1. 24 B
shares:  8. 17 M 571. 81 M 1. 23 B
shares short:  192. 23 K 10. 17 M 13. 00 M
shares short prior month:  253. 19 K 9. 54 M 17. 33 M
short ratio:  4. 68   5. 41   3. 28  
short % of float:  1. 67 % 5. 45 % 2. 38 %
total cash/share:  2. 96   11. 14   9. 33  
total cash:  61. 64 M 6. 71 B 7. 15 B
free cash flow:  -19. 63 M 3. 58 B 2. 96 B
operating cash flow:  -31. 84 M 4. 15 B 4. 30 B

book value:  2. 38   12. 78   26. 92  
price/book:  2. 67   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  22. 38 % --- ---
1-yr mean volatility:  -0. 22 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 72   2. 40   4. 10  
forward EPS:  -1. 88   3. 97   7. 13  
P/E:  -3. 69   13. 63   22. 72  
forward P/E:  -3. 38   -15. 95   13. 99  
PE/G:  0. 38   -1. 65   -1. 32  
growth:  -9. 61 % 127. 12 % 29. 61 %
earnings high:  -0. 45   1. 00   1. 66  
earnings avg:  -0. 49   0. 77   1. 53  
earnings low:  -0. 51   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -27. 55 % -2. 75 % 4. 55 %
return on equity:  -53. 88 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  0. 74   1. 25   0. 93  
sharpe (1yr):  -0. 81   0. 37   0. 70  

held % insiders:  8. 27 % 6. 39 % 3. 38 %
held % institutions:  88. 36 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ALNA
.    + 0.801 =         0.801 :: INITIAL WEIGHT
.   + 42.676 =        43.477 :: spline projection addition
.    x 1.431 =        62.234 :: industry recommendation factor
.    x 2.927 =       182.128 :: symbol recommendation factor
.    x 0.997 =       181.627 :: return on assets factor
.    x 0.995 =       180.648 :: return on equity factor
.    x 2.011 =       363.271 :: current ratio factor
.     x 1.05 =       381.544 :: quick ratio factor
.    x 1.102 =       420.336 :: short ratio factor
.    x 2.027 =       851.901 :: price-to-book factor
.    x 1.197 =      1019.431 :: debt-to-equity factor
.    x 2.112 =      2153.059 :: P/E weight
.     x 1.27 =      2734.376 :: PE/G factor
.    x 1.717 =      4694.149 :: beta factor
.    x 0.807 =      3788.711 :: sharpe factor
.    x 1.049 =      3973.317 :: target low factor
.    x 1.242 =      4933.312 :: target mean factor
.     x 0.98 =      4835.426 :: target high factor
.     x 1.31 =      6333.866 :: industry 2-weeks return factor
.    x 0.934 =      5918.426 :: "drift" penalty 1 days ago
.    x 0.925 =      5475.115 :: "drift" penalty 3 days ago
.     x 0.94 =      5147.401 :: "drift" penalty 5 days ago
.     x 0.94 =      4836.526 :: overall "drift" factor
.    x 0.776 =      3753.873 :: largest single-day jump factor
.    x 0.092 =       346.618 :: low price factor
.      x 1.0 =       346.562 :: factor hist industry gain for week 16
.   cubeRoot =         7.024 :: reduced to standardize
.   - 23.265 =         0.574 :: add/subtract for performance
.                      0.574 :: FINAL WEIGHT for NASDAQ:ALNA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org